WAVE Life Sciences (WVE) Misses Q2 EPS by 22c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Wave Life Sciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
March 2, 2020 6:45 AM ESTInnovative pipeline of stereopure oligonucleotides focused on CNS diseases
32 mg data from both PRECISION-HD clinical trials on track for 2H 2020
Two additional CNS programs SNP3 and C9orf72 on track to initiate clinical development in 2H 2020
Wave to host investor conference call and webcast at 8:00 a.m. ET today
CAMBRIDGE, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today... More
